Karyopharm Therapeutics officially executed a 1-for-15 reverse stock split of its issued and outstanding common stock. The corporate action was implemented to increase the per-share market price of its common stock to regain and maintain compliance with the minimum bid price listing requirements mandated by the Nasdaq Global Select Market. This adjustment consolidated issued shares while proportionately modifying authorized share pools and equity incentive plans without altering the underlying fundamental operations of the business.